Navigation Links
Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease

SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA). The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.

In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.

"By selectively shutting down the Classical Complement pathway with an antibody, the main drivers of anemia in CAD have been reduced in this preclinical study. Using TNT003 and a large number of 40 patient samples, we were able to deepen the field's understanding of the Complement system's role in this rare disease. The study strengthens the hypothesis that such an approach could be beneficial in this rare patient population," stated Sandip Panicker, PhD, C1s Program Lead and senior author on the journal article in Blood.

TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.

Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."


Contact: Kathryn Morris
The Yates Network

Related medicine news :

1. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
2. Human stem cells predict efficacy of Alzheimer drugs
3. Osteoporosis drugs compared for side effects, efficacy in Loyola study
4. Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends
5. CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
6. Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
7. Registry confirms TAVI efficacy and safety in Asian patients
8. Minocycline Enhances the Efficacy of Perispinal Enbrel in Traumatic Brain Injury Treatment as well as Stroke Treatment and Alzheimer’s Treatment
9. CycleBeads Natural Birth Control Method Ranks High in Perfect Use and Typical Use Efficacy According to Most Recent Review of Global Family Planning Reports
10. Study shows long-term efficacy of minimally invasive therapy for patients with Barretts esophagus
11. Muscular Development Store Comments on Efficacy of Protein Blends
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... With FCPX Overlay: Grit , users can apply a ... possibilities are truly endless, all with a click of a mouse. Each user has ... flip, depth of field and more, all within Final Cut Pro X. , With ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes ... and support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact ...
(Date:11/30/2015)... Turks & Caicos Islands, BWI (PRWEB) , ... December 01, 2015 ... ... in 2015. Recently Caribbean Journal, one of the leading digital news sites highlighting ... The top reason? The weather. While much of North America shivers under chilly ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... the19th Bi-National Convention of the Federation of Philippine American Chambers of Commerce held ... Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate from the ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 ... "Orphan Drugs Market 2015-2019" report to their ... the addition of the "Orphan Drugs Market ... Research and Markets ( ) has ... Market 2015-2019" report to their offering. ...
(Date:11/30/2015)... Nov. 30, 2015   Royal Philips (NYSE: ... the industry,s first MRI guided user interface and automatic ... patients with MR Conditional implants, such as knee and ... 2015 Radiological Society of North America Annual Meeting (RSNA) ... supports diagnostic confidence of this growing patient population. ScanWise ...
(Date:11/30/2015)... November 30, 2015 ... adds a 2015 publication ... - 2015 with comprehensive analysis of ... of deal types, such as Mergers ... . ...
Breaking Medicine Technology: